ArticleDigestive diseases and sciences2011
Epigenetic inactivation of the SFRP1 gene in esophageal squamous cell carcinoma.
Article in Digestive diseases and sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Understanding the Epigenetic Landscape of Barrett's Esophagus and Esophageal Cancer: A Review of Current Findings, Caveats and Future Directions.Genes, chromosomes & cancer · 2026Review
- DNA methylation markers in esophageal cancer.Frontiers in genetics · 2024Review
- Construction and validation of a novel and superior protein risk model for prognosis prediction in esophageal cancer.Frontiers in genetics · 2022Article
- The Impact of Infectious Complications after Esophagectomy for Esophageal Cancer on Cancer Prognosis and Treatment Strategy.Journal of clinical medicine · 2021Review
- Article
- SFRP1 in Skin Tumor Initiation and Cancer Stem Cell Regulation with Potential Implications in Epithelial Cancers.Stem cell reports · 2020Article
- Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta-analysis.Oncology letters · 2019Article
- Prognostic Relevance of SFRP1 Gene Promoter Methylation in Colorectal CarcinomaAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update.Open biology · 2017Review
- Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.Oncotarget · 2017Article
- Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers.Clinical and translational medicine · 2016Review
- Expression and prognostic value of SFRP1 and β-catenin in patients with glioblastoma.Oncology letters · 2016Article
- Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma.Clinical and translational science · 2015Article
- MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation.Neuro-oncology · 2014Article
- Review of the alterations in DNA methylation in esophageal squamous cell carcinoma.Surgery today · 2013Review
- Oncogenic features of PHF8 histone demethylase in esophageal squamous cell carcinoma.PloS one · 2013Article
- Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma.Chinese journal of cancer · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe secreted frizzled-related protein 1 (SFRP1) gene, as a Wnt signaling modulator, is frequently inactivated by promoter methylation in many tumors including gastric cancer, breast cancer, oral squamous cell carcinoma, and esophageal adenocarcinoma. However, the role of SFRP1 in esophageal squamous cell carcinoma (ESCC) is not clear. In this study, we investigated the epigenetic inactivation of the SFRP1 gene in ESCC.
methodsNine ESCC cell lines, two immortalized human esophageal epithelial cell lines, twenty ESCC tissues, and paired adjacent nontumor tissues were analyzed in the study. Methylation-specific polymerase chain reaction (PCR), bisulfite sequencing, reverse-transcription PCR, immunohistochemistry, and chromatin immunoprecipitation assay were used to detect SFRP1 promoter methylation, expression of the SFRP1 gene, and histone modification in the SFRP1 promoter region.
resultsThe SFRP1 promoter was found to be highly methylated in 95% (19/20) of the ESCC tissues and in nine ESCC cell lines, compared with 65% (13/20) of the paired nontumor tissues. Moreover, we confirmed that complete methylation of the SFRP1 gene promoter was correlated with its greatly reduced expression level. After individual treatment with 5-aza-2'-deoxycytidine (DAC) and trichostatin A (TSA), the messenger RNA (mRNA) level of the SFRP1 gene was not obviously rescued in the EC9706 cell line. Combined incubation with DAC and TSA can, however, substantially increase the SFRP1 mRNA expression level in the EC9706 cell line. Chromatin immunoprecipitation assay showed that acetylated histone H3 and H4 were found in the SFRP1 promoter region.
conclusionPromoter hypermethylation of SFRP1 is a frequent event in ESCC. Promoter methylation and histone acetylation may cooperatively regulate expression of the SFRP1 gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.